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Elevated serum levels of cardiac troponin and C-reactive protein are associated with all-cause and
cardiovascular mortality in patients with end-stage renal disease. However, the relationship between these
two biomarker levels and mortality in patients with chronic kidney disease remains unclear. We conducted a
meta-analysis to quantify the association of cardiac troponin and C-reactive protein levels with all-cause and
cardiovascular mortality in patients with chronic kidney disease. Relevant studies were identified by searching
the MEDLINE database through November 2013. Studies were included in the meta-analysis if they reported
the long-term all-cause or cardiovascular mortality of chronic kidney disease patients with abnormally elevated
serum levels of cardiac troponin or C-reactive protein. Summary estimates of association were obtained using a
random-effects model. Thirty-two studies met our inclusion criteria. From the pooled analysis, cardiac troponin
and C-reactive protein were significantly associated with all-cause (HR 2.93, 95% CI 1.97-4.33 and HR 1.21, 95%
CI 1.14-1.29, respectively) and cardiovascular (HR 3.27, 95% CI 1.67-6.41 and HR 1.19, 95% CI 1.10-1.28,
respectively) mortality. In the subgroup analysis of cardiac troponin and C-reactive protein, significant
heterogeneities were found among the subgroups of population for renal replacement therapy and for the
proportion of smokers and the C-reactive protein analysis method. Elevated serum levels of cardiac troponin
and C-reactive protein are significant associated with higher risks of all-cause and cardiovascular mortality in
patients with chronic kidney disease. Further studies are warranted to explore the risk stratification in chronic
kidney disease patients.
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’ INTRODUCTION
The number of patients with chronic kidney disease (CKD),
including end-stage renal disease (ESRD), has increased in
recent years (1), and the mortality of these patients is much
higher than that of the normal population. CKD is associated
with an increased risk for cardiovascular mortality (2), and
cardiovascular causes account for almost half of all deaths in
patients with ESRD (3). Cardiovascular risk-factor control is
urged for addressing the heavy burden of cardiovascular
diseases and adverse events in patients with CKD (1). Studies
have shown that diabetes, hypertension, smoking, age,
and serum albumin, calcium, phosphorus, and parathyroid
hormone levels are associated with all-cause and cardiovas-
cular mortality in patients with CKD (4-10). Novel cardiovas-
cular risk factors, including elevated serum C-reactive protein
(CRP) and cardiac troponin (cTn) levels, are prevalent in these
CKD patients (4). As a marker of inflammation that is critical
to the pathogenesis of atherosclerosis (11), the serum level of
CRP is elevated in more than 70% of patients with ESRD (12),
and the serum level of cTn, a marker of myocardial infarction
(13), may predict death in these patients (14).
Some studies have shown that elevated serum levels of
CTn and CRP are associated with all-cause and cardiovas-
cular mortality in patients with ESRD (14,15). However, the
relationship between the serum levels of these two biomar-
kers and mortality in patients with CKD remains unclear.
Some studies have shown that the serum levels of these two
biomarkers were significantly associated with mortality in
CKD patients (16-19), whereas different results were found in
other studies (4,20,21). We conducted an up-to-date meta-
analysis of published studies to quantify the association of
these two biomarker levels with long-term mortality among
CKD patients.DOI: 10.6061/clinics/2015(04)14
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’ METHODS
The meta-analysis was conducted according to the
checklist of the Meta-Analysis of Observational Studies in
Epidemiology group (22). We performed a systematic search
of relevant studies published through November 2013 in the
MEDLINE database.
Search strategy
Accessing the MEDLINE database, we performed a
literature search for studies published until November 4,
2013 using the following search terms and key words:
‘‘C-reactive protein’’, ‘‘CRP’’, ‘‘troponin’’, ‘‘mortality’’ and
‘‘chronic kidney disease’’. We manually checked the refer-
ence list of retrieved articles to identify any studies that were
not identified from the preliminary literature searches.
Inclusion and exclusion criteria
Studies were included in the meta-analysis if they met the
following criteria: 1) published in the English language; 2)
had a randomized controlled trial or a prospective observa-
tional study design; 3) enrolled patients with CKD, which
was defined as an estimated glomerular filtration rate of less
than 60 mL/min per 1.73 m2 (23); 4) reported the long-term
all-cause mortality or cardiovascular mortality of CKD
patients who had abnormal elevated serum levels of CRP
or cTn; and 5) presented estimates of risk ratios (RRs) or
hazard ratios (HRs) with 95% confidence intervals (CIs) or
reported the data necessary to calculate these values.
Animal, autopsy, and phantom studies were excluded. If
the studies excluded patients with a history of myocardial
infarction, they were also excluded.
Data extraction
Two authors independently extracted the following data
from each retrieved article: study characteristics (design,
population, duration of follow-up, CRP analyzed as a
continuous variable or elevated variable, cardiac troponin
assays, and adjustment), patient characteristics (mean age,
sex, proportion of cardiovascular death, renal replacement
therapy, history of diabetes mellitus, history of cardiovas-
cular disease, history of hypertension, history of tobacco
use), and outcomes (all-cause and cardiovascular mortality).
Statistical analysis
We directly extracted or indirectly estimated hazard
ratios (HRs) from each study and pooled HRs using a
random-effects meta-analysis method. Subgroup analyses for
all-cause and cardiovascular mortalities were conducted
according to the following factors: the baseline population
(Z500 vs. o500); proportion of male patients (Z50% vs.
o50%); mean or average age (Z60 years vs. o60 years);
duration of follow-up (Z2 years vs. o2 years); study design
(prospective observational studies vs. randomized controlled
trials); renal replacement therapy (hemodialysis vs. perito-
neal dialysis vs. hemodialysis or peritoneal dialysis vs.
receiving or not receiving renal replacement therapy vs. not
receiving renal replacement therapy, or ESRD vs. not
receiving renal replacement therapy); adjustment (no adjust-
ment vs. appropriate adjustment vs. inappropriate adjust-
ment; appropriate adjustment was defined as adjusting for
age, history of diabetes mellitus, and history of cardiovas-
cular diseases at the same time, whereas inappropriate
adjustment was defined as not adjusting for age, history of
diabetes mellitus, and history of cardiovascular diseases at
the same time); CRP analysis method (elevated variable vs.
continuous variable); troponin assays (cardiac troponin T
vs. cardiac troponin I); prevalence of diabetes mellitus
(Z30% vs. o30%); prevalence of cardiovascular diseases
(Z30% vs. o30%); prevalence of hypertension (Z50% vs.
o50% or Z80% vs. o80%); proportion of smokers (Z30%
vs. o30%); and proportion of cardiovascular deaths (Z50%
vs. o50%).
To perform the quality assessment, two authors indepen-
dently assessed the study quality using the Downs-Black
criteria (24). The Downs-Black criteria is an instrument
comprising 27 questions that evaluate reporting, external
validity, internal validity (bias and confounding), and
statistical power. All questions received a score of 0 or 1,
with the exception of question 5, which received a score
ranging from 0 to 2, depending on whether the statistical
power of the survey was explicitly stated in the article as
being at least 80%. Thus, the maximum score achievable by
an article was 27 points. Disagreements were resolved by
consensus.
Statistical heterogeneity between studies was evaluated
with the I2 statistic (25). Publication bias was assessed using
the Egger asymmetry test (po0.05 indicating statistical
significance) (26). P-values that were less than 0.05 were
considered statistically significant. All statistical analyses
were carried out with STATA, version 12.0 (Stata Corp,
College Station, Texas).
’ RESULTS
Literature search
The details of the search steps are shown in Figure 1. We
identified and screened 828 articles from our preliminary
search, and 50 clinical trials were identified for title and
Figure 1 - Selection of included studies.
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abstract analysis. Eight articles were published as abstracts
only and were excluded. Seven studies were excluded
because they did not report the hazard ratio or we could
not estimate the hazard ratio due to incomplete statistical
data. One duplicate study and one study that only reported
the odds ratio were also excluded. Among the included
studies, 20 studies were included into the CRP analysis
(4,16,17,27–43), and 17 studies were included into the cTn
analysis (18–20,29,30,32,34,37,44–52).
Study characteristics
The characteristics of the included studies are shown in
Table 1, and the patient characteristics are shown in Table 2.
The total population of the included studies was 21,047, and
most of the patients were male (53.93%). Most studies were
prospective observational studies, and there were 3 rando-
mized controlled studies, which studied CRP (16,17,38).
Aside from the unavailable data, 2,321 cardiac deaths and
2,633 all-cause deaths were reported.
CRP predicting all-cause and cardiovascular
mortality
The pooled HRs of all-cause and cardiovascular mortality in
CKD patients are shown in Figures 2 and 3. Elevated serum
levels of CRP were significantly associated with higher
all-cause (HR 1.21, 95% CI 1.14-1.29) and cardiovascular
(HR 1.19, 95% CI 1.10-1.28) mortality in CKD patients. There
were heterogeneities among studies for both all-cause
(I2=88.8%, po0.001) and cardiovascular (I2=75.9%,
po0.001) mortality.
For all-cause mortality, significant heterogeneities were
found among the subgroups of adjustment (p= 0.003) and
CRP analysis method (po0.001). Studies with appropriate
adjustment showed higher all-cause mortality (HR 1.52, 95%
CI 1.16-1.99) compared with those with inappropriate
adjustment (HR 1.07, 95% CI 1.02-1.11) and no adjustment
(HR 1.39, 95% CI 1.13-1.71). When CRP was analyzed as an
elevated variable, all-cause mortality was higher (HR 1.56,
95% CI 1.28-1.90) than when analyzed as a continuous
variable (HR 1.10, 95% CI 1.03-1.17).
For cardiovascular mortality, significant heterogeneities
were found among the population (p= 0.033), CRP analysis
method (p= 0.012), and proportion of smokers (p= 0.011)
subgroups. A larger population was linked to lower
cardiovascular mortality (HR 1.10, 95% CI 1.04-1.17) com-
pared with a smaller population (HR 1.52, 95% CI 1.14-2.04).
Additionally, when CRP was analyzed as an elevated
variable, cardiovascular mortality was higher (HR 1.44,
95% CI 1.17-1.77) than when analyzed as a continuous
variable (HR 1.09, 95% CI 1.01-1.17). Compared with studies
with a smaller proportion of smokers (HR 1.07, 95% CI
1.01-1.14), those with a larger proportion of smokers (HR 1.42,
95% CI 1.15-1.75) showed higher cardiovascular mortality.
Publication bias was found in the analysis of all-cause
mortality (po0.001) and cardiovascular mortality (po0.001),
indicating the presence of publication bias or other sources of
bias. The funnel plots are shown in Figures 4A and 4B.
Sensitivity analysis
During the sensitivity analysis, excluding three studies
(33,39,42) did not have a significant effect on the relationship
between CRP serum levels and all-cause mortality. Excluding
one study that enrolled patients without ESRD (16) also did
not have a significant effect on the relationship between CRP
serum levels and all-cause mortality. For cardiovascular
mortality, one study was excluded (33), but this exclusion did
not influence the statistical significance of the results.
Excluding three studies that enrolled patients without ESRD
(4,16,17) did not have a significant effect on the relationship
between the serum levels of CRP and cardiovascular
mortality.
Cardiac troponin for predicting all-cause and
cardiovascular mortality
The pooled HRs of all-cause and cardiovascular mortality
in CKD patients are shown in Figures 2 and 3. Elevated
serum levels of cTn were significantly associated with higher
all-cause (HR 2.93, 95% CI 1.97-4.33) and cardiovascular
(HR 3.27, 95% CI 1.67-6.41) mortality in CKD patients.
Additionally, there were heterogeneities among studies for
both all-cause (I2= 94.0%, po0.001) and cardiovascular
(I2=96.4%, po0.001) mortality.
For all-cause mortality, significant heterogeneities were
found among the population (p=0.015) and renal replacement
therapy (p=027) subgroups. Studies with a smaller popula-
tion showed higher all-cause mortality (HR 3.20, 95% CI 2.65-
3.87) compared with a larger population (HR 1.54, 95% CI
0.88-2.70). Additionally, studies with a larger population did
not show a significant association of the serum levels of cTn
with increased all-cause mortality. Studies with different renal
replacement therapies showed different associations of cTn
with all-cause mortality. Studies with an ESRD population
had higher all-cause mortality (HR 3.21, 95% CI 2.02-5.09)
compared with those with a population that did not require
renal replacement therapy (HR 1.75, 95% CI 1.33-2.30).
For cardiovascular mortality, significant heterogeneities were
found in the subgroup of the proportion of cardiovascular
deaths (p=0.043). Studies with a higher proportion of cardio-
vascular deaths had higher cardiovascular mortality (HR 4.18,
95% CI 2.68-6.54) compared with those with a lower proportion
of cardiovascular deaths (HR 1.88, 95% CI 1.00-3.53).
Publication bias was found in the analysis of all-
cause mortality (po0.001) and cardiovascular mortality
(p = 0.014), indicating the presence of publication bias or
other sources of bias. The funnel plots are shown in
Figures 4C and 4D.
Sensitivity analysis
Excluding two studies that enrolled patients without
ESRD (18,19) did not have a significant effect on the
relationship between cTn serum levels and all-cause mortal-
ity. For cardiovascular mortality, one study was excluded
(41), but this exclusion did not influence the statistical
significance of the results. Excluding one study that enrolled
patients without ESRD (18) did not have a significant effect
on the relationship between the serum levels of cTn and
cardiovascular mortality.
Quality assessment
The quality assessment results for the included studies are
shown in Table 1. Studies could reach a maximum of 27
points, divided into 5 different aspects – reporting, external
validity, bias, confounding and power. The scores varied
from 12 to 20, and the average score was 16. Because most of
the included studies were not randomized controlled trials,
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Table 1 - Characteristics of the included articles
Studies Study design Total
patients
Duration
of
follow-up
(months)
Analyzed CRP
as continuous
variable/
elevated variable
Cardiac
troponin
assays (T or I)
Adjustment Downs-
Black criteria
scores
Bo¨ger 2005,
Germany (27)
Prospective
observational
study
445 46.8 Elevated variable N/A Age, hemodialysis duration, gender,
smoking history, body mass index,
medication, history of diabetes
mellitus, history of coronary
artery disease
19
Menon 2005, USA
(16)
Randomized
controlled
study
697 125 Elevated variable N/A Age, gender, race, randomization to
different protein diets and blood
pressure strata, diabetes, current
smoking, low-density lipoprotein
cholesterol, high-density
lipoprotein cholesterol, body mass
index, systolic blood pressure,
etiology of kidney disease
16
Tripepi 2005, Italy
(28)
Randomized
controlled
study
217 41 Elevated variable N/A Cardiovascular death, namely age,
gender, smoking, diabetes,
systolic BP, previous
cardiovascular events, asymmetric
dimethylarginine
17
Hocher 2008,
Germany (29)
Randomized
controlled
study
230 52 Elevated variable T No adjustment 15
Hocher 2003,
Germany (30)
Randomized
controlled
study
245 25 Elevated variable T No adjustment 16
Panichi 2008, Italy
(31)
Randomized
controlled
study
757 30 Elevated variable N/A No adjustment 14
Boulier 2004,
France (32)
Randomized
controlled
study
191 13 Elevated variable I Age, sex, duration of dialysis,
diabetes, smoking, hypertension,
dialysis center, HD modality, total
cholesterol, triglycerides
16
Shlipak 2005, USA
(4)
Randomized
controlled
study
1249 103.2 Continuous
variable
N/A Age, sex, race, education, prevalent
cardiovascular disease, elevated
systolic blood pressure, diabetes,
current smoking, HDL of 40 mg/dL
or less, LDL of 130 mg/dL or more,
triglycerides, alcohol use, obesity,
physical activity, left ventricular
hypertrophy, and diuretic use
18
Zoccali 2011, Italy
(33)
Randomized
controlled
study
537 29 Elevated variable N/A Age, gender, cardiovascular
comorbidities, Kt/V and dialysis
duration
18
Paniagua 2010,
Mexico (34)
Randomized
controlled
study
753 16 Continuous
variable
T No adjustment 15
Rao 2008, USA (35) Randomized
controlled
study
182 78 Continuous
variable
N/A No adjustment 14
Kawaguchi 2011,
International (36)
Randomized
controlled
study
2181 24 Continuous
variable
N/A Age, sex, vintage, BMI, spKt/V,
hemoglobin, albumin, calcium,
phosphorus, nPCR, BUN,
creatinine, white blood cell count,
total cholesterol, uric acid,
ferritin, dialysis time, coronary
artery disease, diabetes mellitus
and other comorbidities
18
deFilippi 2003, USA
(37)
Randomized
controlled
study
224 27 Elevated variable T Age, white race, sex, length of time
receiving dialysis, history of
smoking, coronary disease, or
diabetes, levels of albumin,
dialysis dose (Kt/V), BSA
20
McMurray 2011,
International (17)
Randomized
controlled
study
4038 42.5 Elevated variable N/A Age, serum albumin, coronary heart
disease, diabetes complications,
arrhythmia, glycated hemoglobin,
reticulocytes, BUN,
cerebrovascular disease, gender,
race, hemoglobin level, treatment,
smoking status, heart rate, BMI,
and other confounding factors
20
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the questions about blinding and randomizing were scored 0
in most of the studies.
’ DISCUSSION
Elevated serum levels of cTn and CRP were found to be
significantly associated with higher risks of all-cause and
cardiovascular mortality in patients with CKD, according to
our meta-analysis. Compared with CRP, cTn was more
strongly associated with all-cause (HR 2.93 vs. 1.21) and
cardiovascular (HR 3.27 vs. 1.19) mortality.
In our meta-analysis, CRP was significantly associated
with increased all-cause and cardiovascular mortality,
although the association was not as strong as that for
cTn. In the subgroup analyses, significant heterogeneities
were found in the subgroups of adjustment, CRP analysis
method and population. These results indicated that a
larger population might lead to lower cardiovascular
Table 1. (continued )
Studies Study design Total
patients
Duration
of
follow-up
(months)
Analyzed CRP
as continuous
variable/
elevated variable
Cardiac
troponin
assays (T or I)
Adjustment Downs-
Black criteria
scores
Schneider 2013,
International (38)
Randomized
controlled
study
2776 38.4 Continuous
variable
N/A No adjustment 18
McMahon 2012,
Australia (39)
Randomized
controlled
study
302 24 Continuous
variable
N/A Age, duration of dialysis, peripheral
vascular disease, ESA dose,
hemoglobin
17
Stenvinkel 2002,
International (40)
Randomized
controlled
study
663 33±1 Elevated variable N/A Age, body mass index, renal center,
gender
15
Kalantar-Zadeh
2004, USA (41)
Randomized
controlled
study
378 12 Elevated variable N/A Age, gender, race, ethnicity,
insurance status, diabetes mellitus,
Charlson co-morbidity score,
dialysis vintage, dialysis dose, BMI
history of cardiovascular disease
18
Nascimento 2004,
International (42)
Randomized
controlled
study
180 21 Continuous
variable
N/A Event-free times for age, SGA, CRP,
S-Alb, fibrinogen, gender
17
Grootendorst 2007,
International (43)
Randomized
controlled
study
840 36 Elevated variable N/A Age, gender, PKD, Khan
comorbidity score, BMI, smoking
habit, GFR
16
Acharji 2012, USA
(18)
Randomized
controlled
study
2179 12 N/A T and I Differences in baseline clinical, ECG,
laboratory findings
20
Dierkes 2000,
Germany (44)
Randomized
controlled
study
102 24 N/A T Age, time on dialysis, baseline
diabetes, cerebrovascular disease
18
Apple 2002, USA
(45)
Randomized
controlled
study
733 36 N/A T and I Age, pre-draw history of coronary
artery disease, time since initial
hemodialysis
17
Hocher 2004,
Germany (46)
Randomized
controlled
study
245 38 N/A T No adjustment 15
Ooi 1999, Canada
(20)
Randomized
controlled
study
172 12 N/A T No adjustment 12
Ishii 2001, Japan
(47)
Randomized
controlled
study
100 24 N/A T No adjustment 12
Deegan 2001, UK
(48)
Randomized
controlled
study
73 15 N/A T No adjustment 12
Peetz 2003,
Germany (49)
Randomized
controlled
study
104 6 N/A T and I No adjustment 12
Yakupoglu 2002,
Turkey (50)
Randomized
controlled
study
38 48 N/A I No adjustment 13
Stolear 1999,
Belgium (51)
Randomized
controlled
study
94 12 N/A T No adjustment 14
Lo¨wbeer 2002,
Sweden (52)
Randomized
controlled
study
26 48 N/A T No adjustment 13
Wood 2003, UK (19) Randomized
controlled
study
96 24 N/A T Age, sex, diabetes mellitus, history
of cardiovascular disease, serum
creatinine
17
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Table 2 - Patient characteristics in included articles.
Studies Average or
median age
(years old)
Male
(%)
Cardiovascular
death (%)
Renal
replacement
therapy
History of
diabetes
mellitus (%)
History of
cardiovascular
diseases (%)
History of
hypertension
(%)
History of
tobacco
use (%)
Bo¨ger 2005,
Germany (27)
67.5±8.2 54.83 38.69 Hemodialysis 100 57 N/A 44
Menon 2005,
USA (16)
51±12 58.11 51.45 Receiving or not
receiving renal
replacement
therapy
4 N/A N/A 10
Tripepi 2005, Italy (28) 60.7±15.1 55 58.04 Hemodialysis or
peritoneal
dialysis
15 49 45 40
Hocher 2008,
Germany (29)
65.6±13.7 48.7 47.5 Hemodialysis 33 27 91.74 41
Hocher 2003,
Germany (30)
65.6±7.2 50.20 56.16 Hemodialysis 34 64 89.8 41
Panichi 2008, Italy
(31)
66±14 60.5 45.49 Hemodialysis 19 26 35 N/A
Boulier 2004, France
(32)
66.7 50.8 44.83 Hemodialysis 20 33 22.5 27
Shlipak 2005, USA (4) 75±6 47 N/A Receiving or not
receiving renal
replacement
therapy
17 N/A N/A 10
Zoccali 2011, Italy (33) 63±15 57.73 63.19 Hemodialysis 16 27 49 11
Paniagua 2010,
Mexico (34)
48.64±17.55 55.11 46.7 Hemodialysis or
peritoneal
dialysis
44 15.9 N/A N/A
Rao 2008, USA (35) 62.2±12.3 47 35.51 Hemodialysis 41 66 N/A 54
Kawaguchi 2011,
International (36)
62.4±12.6 58.6 N/A Hemodialysis 33 29 72.08 18
deFilippi 2003, USA
(37)
62 54 53 Hemodialysis 48 36 N/A 21
McMurray 2011,
International (17)
67.5±10.76 42.74 N/A Not receiving
renal
replacement
therapy
65.82 36.5 N/A 43.86
Schneider 2013,
International (38)
64.2±8.7 62.18 N/A Hemodialysis 26.4 51.4 N/A 15.5
McMahon 2012,
Australia (39)
60±14 63.9 88.4 Hemodialysis or
peritoneal
dialysis
18.5 88.4 88.4 N/A
Stenvinkel 2002,
International (40)
59.4±1 56.41 N/A Hemodialysis or
peritoneal
dialysis
0.243 N/A N/A N/A
Kalantar-Zadeh 2004,
USA (41)
54.5±14.7 53.2 51.28 Hemodialysis 55.1 50.8 N/A N/A
Nascimento 2004,
International (42)
49±25 55 52 Hemodialysis 9 N/A 26 N/A
Grootendorst 2007,
International (43)
59.1±14.9 60.1 46.9 Hemodialysis or
peritoneal
dialysis
20.7 34.9 N/A N/A
Acharji 2012, USA (18) 76 (troponin
positive)
75 (troponin
negative)
53.46 57.3 Not receiving
renal
replacement
therapy
28.92 33.25 76.95 14.84
Dierkes 2000,
Germany (44)
64±13 49.02 39.29 Hemodialysis 40.2 21 N/A 44
Apple 2002, USA (45) 62 56 N/A Hemodialysis 46 29 N/A N/A
Hocher 2004,
Germany (46)
63.5±5.8 50.2 65.42 Hemodialysis 34.29 64.08 89.8 41.22
Ooi 1999, Canada (20) 61 (cTnTo0.1 mg/L)
64.5 (0.1 mg/
LrcTnTr0.2 mg/L)
62.8 (cTnT4
0.2 mg/L)
64.47 38.71 Hemodialysis 29.07 31.4 43.6 N/A
Ishii 2001, Japan (47) 58 61 52.63 Hemodialysis or
peritoneal
dialysis
41 22 71 N/A
Deegan 2001, UK (48) 64±18 57.53 57.14 Hemodialysis 16.44 24.66 N/A N/A
Peetz 2003,
Germany (49)
63 (male)65
(female)
60.58 85 Hemodialysis 26.92 37.5 70.19 N/A
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mortality and that analyzing a large population as
a continuous variable would lower the all-cause and
cardiovascular mortality. More appropriate adjustments
would lead to higher all-cause mortality. However, notably,
there were heterogeneities in the subgroups of study
design, mean or average age, renal replacement therapy,
and the prevalence of hypertension for cardiovascular
mortality, although the p-values were 40.05. Randomized
controlled trials, studies with younger patients and studies
with fewer hypertension patients showed no significant
results. In the subgroup of renal replacement therapy,
the situation was similar. CRP is a biomarker of inflamma-
tion. CKD patients are subject to multiple nonvascular
inflammatory stimuli, including chronic infection (53).
Figure 2 - C-reactive protein and cardiac troponin for predicting all-cause mortality. Elevated serum levels of C-reactive protein and
cardiac troponin were significantly associated with all-cause mortality in patients with chronic kidney disease. However, the pooled HR
of cardiac troponin was higher than that of C-reactive protein. HR, hazard ratio; CI, confidence interval.
Table 2. (continued )
Studies Average or
median age
(years old)
Male
(%)
Cardiovascular
death (%)
Renal
replacement
therapy
History of
diabetes
mellitus (%)
History of
cardiovascular
diseases (%)
History of
hypertension
(%)
History of
tobacco
use (%)
Yakupoglu 2002,
Turkey (50)
55.9±12.9 42.11 100 Hemodialysis N/A N/A N/A N/A
Stolear 1999,
Belgium (51)
62.9±1.4 58.51 58.33 Hemodialysis 18.09 30.85 N/A N/A
Lo¨wbeer 2002,
Sweden (52)
58 50 73.33 Peritoneal
dialysis
19 19 62 N/A
Wood 2003,
UK (19)
52.4 66.67 90.48 Not receiving
renal
replacement
therapy
14.6 24 N/A N/A
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Therefore, not surprisingly, elevated serum levels of CRP
were found to be associated with higher all-cause and
cardiovascular mortality due to inflammation. However, in
the population with CKD, CRP elevation may also result
from decreased renal clearance or degradation rather than
increased production. This might explain the decreased
statistical association of CRP with mortality (4). Thus,
study characteristics, such as age, population, or renal
replacement therapy, might affect the findings of the
relationship between CRP and mortality, as we found
in the subgroup analysis. This result suggests that screen-
ing CKD patients with elevated CRP for infectious or
non-infectious inflammation and treating with proper
interventions may improve patient outcomes.
We found that cTn was strongly associated with increased
all-cause and cardiovascular mortality. However, patients
who were not receiving renal replacement therapy showed
significantly lower all-cause mortality compared with ESRD
patients. Not surprisingly, ESRD patients were subject to
infection, acute myocardial infarction, and death due to renal
failure. Notably, in the subgroup analysis, the studies with a
larger population showed no significant association of cTn
with all-cause and cardiovascular mortality. Additionally,
studies with younger patients, appropriate adjustment, a
smaller prevalence of cardiovascular diseases, and a smaller
proportion of cardiovascular deaths showed no significant
association of cTn with cardiovascular mortality. cTn is
specific for identifying myocardial cell injury. The elevation
of cTn in CKD patients may result from microembolization
(54), non-ischemic cardiomyopathy or left ventricular hyper-
trophy (55-57). Therefore, cTn elevation was found to be
strongly associated with increased cardiovascular mortality
in CKD patients. The association of cTn elevation with
increased all-cause mortality might be the result of a large
proportion of cardiovascular deaths in CKD patients. (3) In
the population with fewer cardiovascular risk factors, as we
found in the subgroup analysis, cTn elevation might not be a
predictor. One possible explanation is the decreased renal
clearance or degradation of cTn in CKD patients, but more
mechanisms should be explored. According to the present
results, screening for cardiovascular diseases and performing
more active treatment may improve patient outcomes is
suggested when serum levels of cTn are elevated in patients
with CKD.
The strengths of this meta-analysis are the large number of
patients analyzed and the robustness of the findings by
sensitivity analyses. However, there were some limitations to
this study. First, although we conducted an unrestricted
Figure 3 - C-reactive protein and cardiac troponin for predicting cardiovascular mortality. Elevated serum levels of C-reactive protein and
cardiac troponin were significantly associated with cardiovascular mortality in patients with chronic kidney disease. However, the
pooled HR of cardiac troponin was higher than that of C-reactive protein. HR, hazard ratio; CI confidence interval.
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literature search, few studies were randomized controlled
trials, few studies enrolled patients who did not need to
receive renal replacement therapy, and few studies included
a large population. Along with causing publication bias,
these limitations would tend to overinflate the pooled
estimate of HR. However, we did find a significant
association of cTn and CRP with mortality in the sensitive
analyses. Second, the studies included in our analysis used
different cut-off points to define an elevation in the serum
levels of cTn and CRP. This variation in cut-off point is at
least in part related to the significant heterogeneity. Third,
the inclusion criteria of included studies were not well
balanced. Population differences might therefore influence
our results.
In conclusion, the present meta-analysis shows that
elevated serum levels of cTn and CRP are significantly
associated with higher risks of all-cause and cardiovascular
mortality in patients with CKD. Further studies with strict
standardization, long-term follow up, rigorous design, and
large and representative populations are warranted to
explore the risk stratification in CKD patients.
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